| Haven Of Sandpointe, Llc | |
| 2222 South Avenue A, Yuma, Arizona 85364 | |
| (928) 783-8831 | |
| Name | Haven Of Sandpointe, Llc |
|---|---|
| Location | 2222 South Avenue A, Yuma, Arizona |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 143 |
| Occupancy Rate | 55.87% |
| Medicare ID (CCN) | 035096 |
| Legal Business Name | Haven Of Sandpointe Llc |
| Ownership Type | For Profit - Limited Liability Company |
| NPI Number | 1003894841 |
| Organization Name | AMITY FELLOWSERVE INC. |
| Doing Business As | PALM VIEW REHABILITATION & CARE |
| Address | 2222 S Avenue A, Yuma, AZ 85364 |
| Phone Number | 928-783-8831 |
News Archive
How someone perceives color is determined by how the item they are looking at scatters and emits light. In August, three City College of New York physicists affiliated with the Institute for Ultrafast Spectroscopy and Lasers (IUSL) were awarded a patent for a method for changing perception of skin tone by applying quantum and optical principles to cosmetic preparations.
UT Southwestern Medical Center researchers have discovered a mutation that causes a rare systemic disorder known as X-linked reticulate pigmentary disorder (XLPDR) and, significantly, the unexpected cellular mechanism by which the mutation causes the disease.
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to TxCell's Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of chronic non-infectious uveitis.
BioDelivery Sciences International, Inc. announced today that it engaged in a positive pre-New Drug Application meeting with the U.S. Food and Drug Administration regarding BUNAVAIL for the maintenance treatment of opioid dependence.
› Verified 6 days ago
| NPI Number | 1538709324 |
| Organization Name | HAVEN HEALTH SANDPOINTE |
| Address | 2222 S Avenue A, Yuma, AZ 85364 |
| Phone Number | 928-783-8831 |
News Archive
How someone perceives color is determined by how the item they are looking at scatters and emits light. In August, three City College of New York physicists affiliated with the Institute for Ultrafast Spectroscopy and Lasers (IUSL) were awarded a patent for a method for changing perception of skin tone by applying quantum and optical principles to cosmetic preparations.
UT Southwestern Medical Center researchers have discovered a mutation that causes a rare systemic disorder known as X-linked reticulate pigmentary disorder (XLPDR) and, significantly, the unexpected cellular mechanism by which the mutation causes the disease.
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to TxCell's Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of chronic non-infectious uveitis.
BioDelivery Sciences International, Inc. announced today that it engaged in a positive pre-New Drug Application meeting with the U.S. Food and Drug Administration regarding BUNAVAIL for the maintenance treatment of opioid dependence.
› Verified 6 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
How someone perceives color is determined by how the item they are looking at scatters and emits light. In August, three City College of New York physicists affiliated with the Institute for Ultrafast Spectroscopy and Lasers (IUSL) were awarded a patent for a method for changing perception of skin tone by applying quantum and optical principles to cosmetic preparations.
UT Southwestern Medical Center researchers have discovered a mutation that causes a rare systemic disorder known as X-linked reticulate pigmentary disorder (XLPDR) and, significantly, the unexpected cellular mechanism by which the mutation causes the disease.
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to TxCell's Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of chronic non-infectious uveitis.
BioDelivery Sciences International, Inc. announced today that it engaged in a positive pre-New Drug Application meeting with the U.S. Food and Drug Administration regarding BUNAVAIL for the maintenance treatment of opioid dependence.
› Verified 6 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 18.09 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 3.35 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 79.25 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.66 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 3.7 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.51 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 15.79 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 97.91 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.57 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 25.34 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 14.66 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 7.88 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.98 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 62.78 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 96.04 | 82.93 |
News Archive
How someone perceives color is determined by how the item they are looking at scatters and emits light. In August, three City College of New York physicists affiliated with the Institute for Ultrafast Spectroscopy and Lasers (IUSL) were awarded a patent for a method for changing perception of skin tone by applying quantum and optical principles to cosmetic preparations.
UT Southwestern Medical Center researchers have discovered a mutation that causes a rare systemic disorder known as X-linked reticulate pigmentary disorder (XLPDR) and, significantly, the unexpected cellular mechanism by which the mutation causes the disease.
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to TxCell's Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of chronic non-infectious uveitis.
BioDelivery Sciences International, Inc. announced today that it engaged in a positive pre-New Drug Application meeting with the U.S. Food and Drug Administration regarding BUNAVAIL for the maintenance treatment of opioid dependence.
› Verified 6 days ago
Welbrook Yuma Opco Llc Location: 2271 South Ridgeview Drive, Yuma, Arizona 85364 Phone: (801) 683-6565 |